Significant biosimilar activities this week include 29 May 20 | In a filing to the Securities and Exchange Commission, Alexion announced it has settled its eculizumab dispute...
Pearce IP BioBlast™: w/e 05 Jun 2020
read more
Pearce IP BioBlast™: w/e 29 May 2020
Significant biosimilar activities this week include 25 May 20 | The American Journal of Managed Care reported two cost savings studies presented at a virtual meeting of the...
Pearce IP appoints biotech/pharma IP leader Jacinta Flattery-O’Brien as Special Counsel
Boutique specialist firm Pearce IP is delighted to announce the appointment of biotech/pharma IP leader Jacinta Flattery-O'Brien PhD as Special Counsel. A highly regarded patent...
Pearce IP BioBlast™: w/e 22 May 2020
Significant biosimilar activities this week include 11 May 20 | AstraZeneca announced it had recovered the global rights to brazikumab from Amgen. AstraZeneca had previously...
Pearce IP BioBlast™: w/e 15 May 2020
Significant biosimilar activities this week include 11 May 20 | Healio reported on a new study comparing faricimab to ranibizumab which was presented at a virtual meeting of the...
Pearce IP BioBlast™: w/e 08 May 2020
Significant biosimilar activities this week include 01 May 2020 | AbbVie released its Q1 2020 financial results, reporting a 13.7% increase in US sales of Humira® (adalimumab)...
Pearce IP BioBlast™: w/e 01 May 2020
Significant biosimilar activities this week include 23 April 2020 | Henlius Biotech announced it has received two EU GMP certificates related to its trastuzumab biosimilar HLX02....
Pearce IP BioBlast™: w/e 24 Apr 2020
Significant biosimilar activities this week include 21 Apr 20 | The Centre for Biosimilars reported that Xbrane Pharma was continuing clinical trials of its ranibizumab candidate...
Pearce IP BioBlast™: w/e 17 Apr 2020
Significant biosimilar activities this week include 14 April 20 | Mylan and Biocon launched Fulphila® (pegfilgrastim) in Australia. Fulphila® is indicated for the treatment of...
Pearce IP BioBlast™: w/e 10 Apr 2020
Significant biosimilar activities this week include March 20 | BiosanaPharma released the results of Ph I trials of BP001 (omalizumab), reporting comparability to Xolair®. 06...
Pearce IP BioBlast™: w/e 03 Apr 2020
Significant biosimilar activities this week include 30 Mar 20 | Biocad announced it had received registration certificates from Bosnia and Herzegovina for Acellbia® (rituximab)...
Pearce IP BioBlast™: w/e 27 March 2020
Significant biosimilar activities this week include March 20 | The UK High Court ruled filing errors in a Supplementary Protection Certificate (SPC) for Lucentis®...
Pearce IP BioBlast™: w/e 20 March 2020
Significant biosimilar activities this week include 16 Mar 20 | Teva and Celltrion launched Herzuma (trastuzumab) in the US. Herzuma is indicated for the treatment of breast...
Pearce IP BioBlast™: w/e 13 March 2020
Significant biosimilar activities this week include 09 Mar 20 | The FDA and FTC held a public workshop to further their efforts in creating a better biosimilar landscape in the...
Pearce IP BioBlast™: w/e 06 March 2020
Significant biosimilar activities this week include 02 Mar 20 | Celltrion launched Remsima SC, its subcutaneous infliximab product, in the UK. To support the launch,...
Pearce IP BioBlast™: w/e 28 February 2020
Significant biosimilar activities this week include 24 Feb 20 | The FDA launched a searchable version of the 'Purple Book', containing information about FDA licensed biological...
Mark Your Calendars: The End of the AU Innovation Patent System is Set
As we previously foreshadowed, the innovation patent system has been given its end dates: 25 August 2021: last date to lodge innovation patents; and 25 August 2029: date on which...
Pearce IP BioBlast™: w/e 21 February 2020
Significant biosimilar activities this week include 12 Feb 20 | Wockhardt announced divestment of assets to Dr Reddy's, under which 62 products and a manufacturing facility will...
Pearce IP BioBlast™: f/e 07 February 2020
Significant biosimilar activities this fortnight include 05 Feb 20 | Merck announced a new spin-off company which will incorporate products from its Women's Health, Legacy Brands...
Pearce IP BioBlast™: w/e 24 January 2020
Significant biosimilar activities this week include Jan 20 | Genentech and Roche commenced recruitment for Ph III clinical trials of their ranibizumab Port Delivery System (PDS)...
The innovation patent system is nearing its end
The Intellectual Property Laws Amendment (Productivity Commission Response Part 2 and Other Measures) Bill 2019 clears the Senate and heads to the House of Reps What is in the...
New Zealand Introduces Excess Claims Fee in Patent Examination
The Intellectual Property Office of New Zealand (IPONZ) has announced the introduction of excess claims fee, an increase in the examination fee, and increases in...
R’mAb AU: “step down” inj’n saved for another day – short, fixed term, blanket injunction for Sandoz
Today the Federal Court ordered an interlocutory injunction against Sandoz, restraining it from selling biosimilar rituximab (Riximyo) in Australia until 11 August 2019. The 4...
Remicade™ Biosimilars US: Key Remicade™ patent revoked by Fed Cir
J&J suffered another blow today as a key Remicade® (infliximab) patent was revoked by US Court of Appeals (Federal Circuit). Upholding the USPTO decision on reexamination...
Recent BioBlast® Updates
Get our Pearce IP Blogs & BioBlast® sent directly to your inbox
Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.